Paper · 42850682
Mechanism-Informed Language Modeling and Oxygenated 3D Screening Identify Berberine-Enzalutamide Synergy in Prostate Cancer Models.
Lo CH and 15 others. Adv Sci (Weinh), 2026.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. Mechanism-Informed Language Modeling and Oxygenated 3D Screening Identify Berberine-Enzalutamide Synergy in Prostate Cancer Models. Papers, record 42850682. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42850682
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanism-Informed Language Modeling and Oxygenated 3D Screening Identify Berberine-Enzalutamide Synergy in Prostate Cancer Models.
- Journal
- Adv Sci (Weinh)
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-13
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants20
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| HT9425-25-1-0290 | U.S. Department of Defense | PubMed | PubMed | ||
| R37CA240822 | NCI NIH HHS | United States | R37CA240822 | PubMed | NIH RePORTER |
| R01 CA274978 | NCI NIH HHS | United States | R01CA274978 | PubMed | NIH RePORTER |
| 20245682 | Neuroendocrine Tumor Research Foundation | PubMed | PubMed | ||
| Mike Slive Foundation for Prostate Cancer Research | PubMed | PubMed | |||
| R01CA287669 | NCI NIH HHS | United States | R01CA287669 | PubMed | NIH RePORTER |
| HT9425-24-1-0396 | U.S. Department of Defense | PubMed | PubMed | ||
| R01 CA287669 | NCI NIH HHS | United States | R01CA287669 | PubMed | NIH RePORTER |
| R01CA274978 | NCI NIH HHS | United States | R01CA274978 | PubMed | NIH RePORTER |
| DBI-2325121 | National Science Foundation | PubMed | PubMed |
1 to 10 of 20
See all 20 grantsTrials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Update of | 41,659,618 | Mechanistic Language Modeling and Oxygenated 3D Screening Reveal Berberine and Enzalutamide Synergy in Resistant Prostate Cancer. | https://conductscience.org/library/papers/41659618 |
Source PubMed
References61
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 18,264,981 | Energy metabolism transition in multi-cellular human tumor spheroids. | J Cell Physiol | 2008 | https://conductscience.org/library/papers/18264981 | PubMed |
| 2 | 37,852,959 | miR-28-based combination therapy impairs aggressive B cell lymphoma growth by rewiring DNA replication. | Cell Death Dis | 2023 | https://conductscience.org/library/papers/37852959 | PubMed |
| 3 | 18,008,377 | Androgen signaling and its interactions with other signaling pathways in prostate cancer. | Bioessays | 2007 | https://conductscience.org/library/papers/18008377 | PubMed |
| 4 | 34,571,537 | DeepDDS: deep graph neural network with attention mechanism to predict synergistic drug combinations. | Brief Bioinform | 2022 | https://conductscience.org/library/papers/34571537 | PubMed |
| 5 | 26,378,018 | Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. | Oncotarget | 2015 | https://conductscience.org/library/papers/26378018 | PubMed |
| 6 | 36,321,951 | Emulsification by vitamin E TPGS or Quillaja extract enhanced absorption of berberine without affecting its metabolism in humans. | Food Funct | 2022 | https://conductscience.org/library/papers/36321951 | PubMed |
| 7 | 25,649,766 | Intracrine Androgens and AKR1C3 Activation Confer Resistance to Enzalutamide in Prostate Cancer. | Cancer Res | 2015 | https://conductscience.org/library/papers/25649766 | PubMed |
| 8 | 33,663,530 | Challenges of applying multicellular tumor spheroids in preclinical phase. | Cancer Cell Int | 2021 | https://conductscience.org/library/papers/33663530 | PubMed |
| 9 | 39,221,997 | DTI-LM: language model powered drug-target interaction prediction. | Bioinformatics | 2024 | https://conductscience.org/library/papers/39221997 | PubMed |
| 10 | 40,240,608 | Perturbing LSD1 and WNT rewires transcription to synergistically induce AML differentiation. | Nature | 2025 | https://conductscience.org/library/papers/40240608 | PubMed |
1 to 10 of 61
See all 61 referencesCited by0
The papers in our copy of PubMed whose reference list names this one, newest first.
None in this release.
Genes0
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
None in this release.
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42850682
GET https://conductscience.org/api/papers/v1/42850682/references?page=2